老年晚期肺癌患者药物选择.pptVIP

* * [9]Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase Ⅲrandomized trial[J]. J Natl Cancer Inst, 2003, 95(5): 362-372. Gridelli C, et al. J Natl Cancer Inst, 2003, 95(5): 362-372. * * * * [10]蒋京伟，梁晓华，周鑫莉，等 . 卡铂与顺铂治疗晚期非小细胞肺癌疗效的荟萃分析[J]. 中华医学杂志，2006，86（37）：2615-2620. [11]Hiroshi Takatani, Yoichi Nakamura, Seiji Nagashima, et al. Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non–small-cell lung cancer[J]. Clin Lung Cancer, 2012 Jan 18. [10]蒋京伟，等 . 中华医学杂志，2006，86（37）：2615-2620. [11]Hiroshi Takatani, et al. Clin Lung Cancer, 2012 Jan 18. * [12]Resell R，Carcereny E，Gervais R，et a1．Erlotinib versus standard chemotherapy as first—line treatment for European patients with advanced EGFR mutation-positive non-smal1．eell lung cancer(EURTAC)：a muhicentre，open—label。randomised phase 3 trial[J]．Lancet Once1，2012，3(3)：239-246. [12]Resell R，et a1．Lancet Once1，2012，3(3)：239-246. * [13]Khozin S，Blumenthal GM，Jiang X，et a1．U．S．Food and Drug Administration approval summary： Erlotinib for the first—line treatment of metastatic non—small eell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 2l (L858R) substitution mutations[J]．Oncologist，2014，19(7)：774-779． [13]Khozin S，et a1．Oncologist，2014，19(7)：774-779． * [14]SandierA，GrayR，PerryMC，et a1．Paelitaxel—earboplatinalone or with bevacizumab for non—small-celI lung cancerf J]．N Engl J Med，2006，355(24)：2542．2550 [15]Ramalingam SS，Dahlberg SE，Langer CJ，et a1．Outcomes for elderly，advanced—stage non small-cell lung cancer patients treated with bevaeizumab in combination with carboplatin and paclitaxel：analysis ofEastern Cooperative Oncology Group al 4599[J]．J Clin Oneel，2oo8，26(1)：60-65． [16]Zhu J，Sharma DB，Gray SW，et a1．Carboplatin and paclitaxel with vs without bevacizumab in